Volver a Agenda
Track 1 Session 5: Oncology Therapeutics: Minimizing Risks for Maximum Benefit
Session Chair(s)
Ritu Jaswal
Vice President - Pharmacovigilance Operations
Parexel, India
The session will commence with a comprehensive overview of Novartis Oncology drugs, emphasizing their therapeutic advantages and clinical applications. This will be followed by an extensive discussion on the safety profiles and risk minimization strategies of approved chemotherapeutic drugs. The session will conclude with insights into risk minimization for developmental oncology drugs, including innovative therapies such as CAR-T and radioligand treatments. The focus throughout will be on enhancing patient outcomes while diligently managing potential risks associated with these treatments.
Speaker(s)
Oncology Therapeutics At Novartis
Anika Rana
Novartis, India
Head Medical Safety Assessment and ESP Engagement
Safety Profile/Risk Minimization Of Approved Chemotherapeutic Drugs
Naveen Chhabra
Novartis, India
Senior Medical Safety Lead
Risk Minimization For Developmental Oncology Drugs Including CAR-T And Radioligand Therapies
Ritu Singal
Novartis, India
Global Program Safety Lead
Learning From The Frontier: Risk Management In CAR-T Cell Immunotherapy For Haematological Malignancies
Anupam Chhabra
Immuneel Therapeutics Private Limited, India
Head of Medical Affairs
¿Tiene una cuenta?